Dr Diarmuid O’Brien has been appointed as the University of Cambridge’s new Pro-Vice-Chancellor for Innovation. He is currently Chief Executive of Cambridge Enterprise, the University’s commercialisation arm which supports academics, researchers, staff and students in achieving knowledge transfer and research impact.

One in 200 newborns is admitted to a neonatal unit with sepsis caused by a bacteria commonly carried by their mothers – much greater than the previous estimate, say Cambridge researchers. The team has developed an ultra-sensitive test capable of better detecting the bacteria, as it is missed in the vast majority of cases.

Researchers have developed a new way of improving diagnosis of bipolar disorder that uses a simple blood test to identify biomarkers associated with the condition.

 An ambitious new strategy to nurture and grow its innovation ecosystem has been unveiled at Cambridge summit.

Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The studies suggest that a single vaccine with combinations of these antigens – a substance that causes the immune system to produce antibodies against it – could protect against an even greater range of current and future coronaviruses.

Cambridge remains the most intensive science and technological cluster in the world – according to a new report ranking innovation around the globe.